Latest From Nektar Therapeutics
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.
Emerging Company Profile: This is the first human study for lead product candidate THOR-707 and for the company's Expanded Genetic Alphabet platform, starting with a recombinant IL-2 that's being tested in solid tumors.
Although only a few companies commented on the FDA's draft guidance on the benefit/risk assessment of new opioids, they cut against conventional wisdom by supporting the agency's desire to see active comparator data.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Immune Disorders
- Neurology, Nervous System
- Inhale Therapeutic Systems Inc.
- Nektar Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Nektar Therapeutics
- Senior Management
Howard W Robin, Pres. & CEO
Gil M Labrucherie, SVP, CFO
Stephen K Doberstein, PhD, SVP, R&D and Chief R&D Officer
- Contact Info
Phone: (415) 482-5300
455 Mission Bay Blvd. S.
San Francisco, CA 94158
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.